Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Changtong Oral Liquid is a Traditional Chinese Medicine (TCM) formulation developed by the Nanfang Hospital of Southern Medical University (formerly the First Military Medical University). It is primarily utilized in the postoperative management of patients undergoing abdominal surgery, particularly for rectal malignant tumors, to prevent the formation of postoperative peritoneal adhesions and intestinal obstruction. The preparation is based on classical purgative formulas and typically contains herbal ingredients such as *Rheum palmatum*, *Magnolia officinalis*, *Aurantii Fructus Immaturus*, and *Mirabilite*. Its therapeutic effects are attributed to the stimulation of gastrointestinal motility and the inhibition of inflammatory pathways. Specifically, it has been shown to downregulate the expression of pro-fibrotic and pro-inflammatory factors such as TGF-beta1, TNF-alpha, and IL-6, thereby reducing the fibroblastic activity that leads to adhesions. It is commonly administered orally or via a gastric tube in the early postoperative phase to facilitate the recovery of bowel function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Changtong Oral Liquid.